PMID- 6449285
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 40
IP  - 10
DP  - 1980 Oct
TI  - Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary 
      cancer cytosolic and nuclear compartments and their relationship to estrogen 
      receptor.
PG  - 3815-20
AB  - Dehydroepiandrosterone (DHEA) and 5-androstene-3 beta,17 beta-diol (ADIOL) were 
      determined by radioimmunoassay in human primary mammary cancer cytosol 
      preparations. The range and means +/- S.D. (ng/g, wet weight, of tissue) in 
      individual tumors were: DHE, 12.3 +/- 14.4, n = 34; and ADIOL, 2.7 +/- 2.1, n = 
      43. In 23 tumors in which both steroids were measured in the same extract, they 
      were significantly correlated, and in these tumors the ratio of ADIOL to DHEA was 
      lower in estrogen receptor (ERC)-negative than in ERC-positive tumors, but this 
      difference was not significant. The ratio of ADIOL to DHEA was 5-fold higher in 
      purified nuclei obtained from pooled primary mammary cancer tissue compared to 
      that in the cytosol. DHEA was present in the cytosol of tumors from premenopausal 
      women in significantly higher concentrations than in cytosols of postmenopausal 
      women [0.73 +/- 0.49 ng/mg cytosol protein (n = 14) versus 0.35 +/- 0.35 (n = 
      19); p < 0.02], whereas the concentrations of ADIOL were similar [0.12 +/- 0.09 
      ng/mg cytosol protein (n = 18) and 0.10 +/- 0.11 (n = 25), for pre- and 
      postmenopausal women, respectively]. In ERC-positive tumors, there was a negative 
      correlation between ERC concentration and cytosol ADIOL levels in both 
      premenopausal (r = -0.46, n = 10) and postmenopausal (r = -0.24; n = 20) subjects 
      and also DHEA levels in postmenopausal women only (r = -0.30; n = 12). However, 
      none of these correlations reached statistical significance. In view of the known 
      high affinity of ADIOL for ERC (Kd approximately 6 nM) and its estrogen-like 
      activity in vivo, these data suggest that the concentration of ADIOL in the tumor 
      cytosols is sufficiently high to translocate ERC and provoke an estrogen 
      response.
FAU - Adams, J B
AU  - Adams JB
FAU - Archibald, L
AU  - Archibald L
FAU - Seymour-Munn, K
AU  - Seymour-Munn K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Androstenediols)
RN  - 0 (Receptors, Estrogen)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - 95PS51EMXY (Androstenediol)
SB  - IM
MH  - Androstenediol/*analysis
MH  - Androstenediols/*analysis
MH  - Breast Neoplasms/*analysis/ultrastructure
MH  - Cell Nucleus/analysis
MH  - Cross Reactions
MH  - Cytosol/*analysis
MH  - Dehydroepiandrosterone/*analysis
MH  - Female
MH  - Humans
MH  - Radioimmunoassay
MH  - Receptors, Estrogen/*analysis
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1980 Oct;40(10):3815-20.